Name

Spherix Global Insights

Legal name

Spherix Global Insights

Website

https://spherixglobalinsights.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Market Intelligence

NAICS

Management, Scientific, and Technical Consulting Services (5416), Other Management Consulting Services (541618), Marketing Consulting Services (541613)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Industry & Sector Research (Syndicated/Custom) (BPAHALAE)

Keywords

• Pharmaceutical market intelligence
• Syndicated healthcare research
• Specialty pharma analytics
• HCP primary research
• Market access advisory

Headquarters

HQ city

Exton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Subscription-based Market Intelligence Reports: Spherix generates revenue through annual and multi-year subscriptions to syndicated research reports and advisory services. Clients receive access to proprietary studies across therapeutic franchises including RealTime Dynamix, Patient Chart Dynamix, Patient Voice Dynamix, Launch Dynamix, Market Dynamix, Special Topix, and account management services. Additional revenue comes from custom strategic advisory sessions, proprietary questions added to surveys, and ad hoc analyses requested by clients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Spherix Global Insights is an independent B2B market intelligence and advisory firm serving the specialty pharmaceutical and biotech industry. It sells syndicated research products (e.g., RealTime Dynamix, Patient Chart Dynamix, Patient Voice Dynamix, Launch Dynamix, Market Dynamix, Special Topix) organized across eight therapeutic franchises plus a dedicated Market Access team, drawing on proprietary communities of vetted physicians, patients, and payer decision-makers. Clients receive subscriptions to quarterly/ongoing studies, access a client portal of dashboards and reports, and engage franchise experts for custom strategic advisory sessions.

Product overview

Spherix Global Insights operates as a specialized market intelligence and advisory services firm offering a comprehensive portfolio of syndicated research products organized across eight therapeutic franchises (Market Access, Dermatology, Gastroenterology, Rheumatology, Nephrology, CNS, Ophthalmology, Hematology/Oncology). The core offerings include RealTime Dynamix (quarterly competitive landscape tracking), Patient Chart Dynamix (large-scale patient chart audits), Patient Voice Dynamix (patient experience research), Launch Dynamix (new product KPI benchmarking), Market Dynamix (market sizing and disruption analysis), and Special Topix (event-driven topic reports). Market Access services encompass Account Management Dynamix, Benefit Design Dynamix, Key Account Dynamix, and Patient Services Dynamix. The company maintains curated communities of physicians, KOLs, payers, and patients, accessible via Client Portal and Physician Portal platforms. The portfolio was expanded in late 2025 to include oncology within the hematology franchise. All services are supported by strategic advisory capabilities and thought leadership resources including white papers and conference presentations.

Differentiator

Problem solved

Functional benefit

Brands

• RealTime Dynamix™: Provides robust, unbiased brand and class trending of KPIs with quarterly market trending and event-driven content
• Patient Chart Dynamix™
• Patient Voice Dynamix™
• Launch Dynamix™
• Market Dynamix™
• Special Topix™
• Account Management Dynamix™
• Benefit Design Dynamix™
• Key Account Dynamix™
• Patient Services Dynamix™

Products and services

• RealTime Dynamix Quarterly or semiannual syndicated reports providing unbiased views of competitive landscapes within specialty pharmaceutical markets, fueled by HCP primary research and expert analysis. Tracks brand use, promotional activity, disease awareness, and pipeline product perceptions.
• Patient Chart Dynamix Large-scale patient chart audits capturing clinical and non-clinical patient demographics along with rationale for treatment choices, revealing real-world patient management and treatment sequencing not available in claims data.
• Patient Voice Dynamix Captures patient experiences, perceptions, and lived experiences navigating diagnosis, treatment, and long-term disease management through qualitative interviews, quantitative surveys, and validated patient-reported outcome measures.
• Launch Dynamix Monthly KPI benchmarking of newly launched products for the first 18 months, augmented by quarterly deep dives including qualitative interviews, focusing on uptake drivers/barriers, promotional activity, patient types, and competitive analyses.
• Market Dynamix Blends data from specialists and leading KOLs to provide market size, current treatment approaches, unmet needs, and expert opinions on likely disruption from pipeline agents over a 3–5 year horizon.
• Special Topix Reports on trending events and topics of interest in specialty markets, providing objective perspective and context into real issues influencing market shifts and prescriber perspectives on disruptive events.
• Account Management Dynamix Evaluates effectiveness of national and regional account teams through the eyes of medical and pharmacy directors at leading health plans and IDNs, benchmarking account team performance versus competitors across key competencies.
• Benefit Design Dynamix Explores how commercial and government payers are evolving benefit design structures, formulary placement decisions, and reimbursement strategies, anticipating drug access trends and policy shifts.
• Key Account Dynamix Provides structured intelligence on leading national and regional payers, IDNs, and specialty pharmacy accounts, including comparative assessments and detailed account profiles for strategic engagement planning.
• Patient Services Dynamix Provides structured intelligence on how patient service programs are experienced across physicians, office staff, patients, and caregivers, enabling manufacturers to evaluate program performance through competitive benchmarking.
• Strategic Advisory Services Industry experts provide strategic advisory services across the product lifecycle, including on-demand advisory, strategic sessions, and thought partnership with Spherix market experts on-site or virtually.
• Spherix Client Portal Secure online portal providing subscribed clients searchable access to Spherix syndicated reports, dashboards, and data from the past 12 months, with advanced release 3+ business days before public release.
• Oncology Franchise Coverage Dedicated oncology syndicated research franchise covering AML, B-cell malignancies, CLL, large B-cell lymphoma, multiple myeloma, MPN, NSCLC, smoldering myeloma, and solid tumors across the same Dynamix research methodologies.

Quantifiable outcome

• Trusted by 19 of top 20 pharmaceutical/biotech organizations
• +1 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Trinity Life Sciences: Trinity Life Sciences is a specialist life sciences strategy and insights firm serving pharma/biotech commercial teams with therapeutic-area expertise and syndicated/commercial intelligence — directly comparable to Spherix's franchise-driven syndicated model.
• Clarivate (Decision Resources Group): Clarivate's DRG unit provides syndicated and custom market intelligence focused on specialty therapeutic areas for pharma/biotech, mirroring Spherix's specialty franchise coverage and syndicated subscription model.
• Kantar Health: Kantar Health delivers syndicated and custom healthcare market research and commercial insights to pharma/biotech, overlapping with Spherix's therapeutic-area syndicated research and advisory offerings.
• ZS Associates: ZS is a management consulting and analytics firm serving pharma/biotech commercial strategy teams, with overlapping advisory and real-world evidence offerings compared to Spherix's strategic advisory and Launch Dynamix-style offerings.
• Cello Health: Cello Health (now operating within the Cello Group/U.S. Pharma Intelligence ecosystem) provides strategic insights and evidence-based consulting to pharma clients, directly comparable to Spherix's syndicated and advisory portfolio.

Broad incumbents

• IQVIA: IQVIA is the largest healthcare data, analytics, and commercial intelligence incumbent serving pharma/biotech globally — offering broader datasets and consulting alongside overlapping syndicated products.
• Informa Pharma Intelligence: Informa Pharma Intelligence operates Citeline/Scrantee-style syndicated databases and commercial intelligence for pharma — a broader incumbent with overlapping therapeutic-area and competitive intelligence coverage.
• Ipsos Healthcare: Ipsos Healthcare is a large multinational healthcare market research practice with syndicated and custom offerings across multiple therapeutic categories — a broader incumbent that competes with Spherix for pharma commercial research budgets.

Emerging players

• Definitive Healthcare: Definitive Healthcare is a publicly listed healthcare commercial intelligence company focused on provider, payer, and biopharma data — partially overlapping with Spherix's payer and market access intelligence offerings.
• Beghou Consulting: Beghou Consulting is a specialized pharma commercial consulting and analytics firm serving biotech and pharma clients with commercial strategy, forecasting, and customer engagement analytics — an emerging player with overlapping therapeutic-area commercial work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/spherix-global-insights
• Xx.com/spherixglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spherix Global Insights